AzTrials
AzTrials

Postpartum HemorrhagePSYCHENCT03120208

Prevalence of Psychological Disorders After Immediate Postpartum Hemorrhage

A study testing • The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11., The GAD-7 with a discrimination threshold ≥10. and • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46 in people with Postpartum Hemorrhage and Postpartum Women, run by University Hospital, Clermont-Ferrand at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this cross-sectional study is to assess the prevalence of depression at 2 months, 6 months, and 1 year postpartum in women who had an immediate postpartum hemorrhage (immediate PPH defined as blood loss ≥ 500 mL within 24 hours of delivery). Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
• The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11., The GAD-7 with a discrimination threshold ≥10. and • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,298 participants
Where
1 siteFrance
Study dates
27 Apr 2017to 2 Apr 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • women who gave birth at a term ≥ 22 weeks' gestation or, if the term is unknown, to a fetus with a birth weight ≥ 500 g),
  • regardless of the type of delivery (vaginal or cesarean),
  • regardless of parity or fetal presentation,
  • and regardless of type of pregnancy (singleton or multiple).
  • and affiliated with French CNAMTS (salaried worker) health insurance.
  • Partner of a woman who gave birth at a term ≥ 22 weeks of gestation or, if the term is unknown, to a fetus with a birth weight ≥ 500 g),
Show all 10Show fewer
  • Regardless of the type of delivery (vaginal or cesarean),
  • Regardless of parity and fetal presentation,
  • And regardless of type of pregnancy (singleton or multiple),
  • And both partners are affiliated with French CNAMTS (salaried worker) health insurance.

Who cannot join

  • Women who are:
  • minors,
  • who do not understand French,
  • who refuse to participate (did not sign consent),
  • and who did not give birth at the Clermont-Ferrand University Hospital Center maternity unit and were secondarily transferred there postpartum.
  • For the partners:
Show all 13Show fewer
  • Partner of a woman who gave birth at a term < 22 weeks of gestation or, if the term is unknown, to a fetus with a birth weight < 500 g),
  • Partner who does not understand French,
  • Who refuses to participate (does not sign consent),
  • Partner who is a minor,
  • Protected adult,
  • Partner not present at the maternity ward (woman is divorced, separated, has no partner, or the partner is abroad or in prison or died during pregnancy),
  • And partners of women who gave birth outside the UHC and was transferred to it only secondarily in the postpartum period.

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63003

Other trials in France

About this study

The objective of this cross-sectional study is to assess the prevalence of depression at 2 months, 6 months, and 1 year postpartum in women who had an immediate postpartum hemorrhage (immediate PPH defined as blood loss ≥ 500 mL within 24 hours of delivery). The potential serious consequences of PPH may lead to a greater number of psychological disorders in these women than in women without PPH.

Read the detailed description

Study design: This repeated, cross-sectional, descriptive and etiological single-center study will take place within a cohort of women giving birth at the Clermont-Ferrand University Hospital Center (Psyche 1), and a cohort of their partners (psyche 2).

Principal endpoint: The prevalence of depression, measured by the Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.

Study plan and procedures:

Psyche 1:

For each woman with a PPH (exposed), 2 women without PPH (not exposed) will be included: the women who gave birth immediately before and immediate after her. If one of these 2 unexposed women eligible for the unexposed group also has a postpartum hemorrhage, another woman immediately just before or after the woman with PPH will be included. The PPH will be managed according to the national guidelines issued in December 2014.

The intervention will consist of 3 questionnaire surveys, at 2 months, 6 months, and 1 year postpartum.

Information and inclusion will take place in the immediate postpartum period at the Clermont-Ferrand University Hospital Center, France. An investigator (midwife or gynecologist-obstetrician in the maternity ward) will inform eligible women about the study, in the postpartum period. This investigator will provide them with a written information sheet and obtain their written consent. If the woman has already left the maternity ward, an investigator will contact her by mail or telephone, and she will receive the information sheet and consent form at her postnatal consultation in the department.

The cohort will complete each questionnaire at the same times in relation to their date of delivery (2 months, 6 months, and 12 months after). They will receive an email asking them to complete the questionnaires, including a participation number and an internet link to the self-administered questionnaires. This intervention is not usually performed for women who give birth at our hospital, whether or not they had a PPH. The procedures, other than the surveys, will be those provided habitually as usual care and will comply with good clinical practices and French regulations (1992 decree, French early discharge guideline from 2004). Should the questionnaire identify a woman in need of immediate psychological care, she will be contacted, referred to, and encouraged to consult a competent professional (psychologist, psychiatrist, child psychiatrist, etc.).

Psyche 2:

The cohort of partners will complete each questionnaire at the same times in relation to the date of delivery (2nd month and 6th month). The "source" documents will be the parturient's medical file (the part concerning both partners) and questionnaires, as the study involves a survey of the partners of women giving birth. The relevant covariables (confounding and prognostic factors) will also be collected from the women's medical files (emergency cesarean, vascular embolization, etc.). These covariables are already being collected as part of the Psyche 1 study.

Inclusion will take place in the immediate postpartum period. Accordingly, in the Psyche 1 study, for every woman with a PPH (exposed), 2 women without PPH (not exposed) are eligible (the woman who gave birth before and after the exposed woman). In this ancillary study, the partners, if eligible, of both the exposed and nonexposed women in the Psyche 1 study will be asked to participate.

The intervention will consist of 3 surveys by questionnaires: during the woman's hospitalization during the immediate postpartum period, at 2 months, and at 6 months after the delivery.

The partners of the women who had an immediate postpartum hemorrhage (PPH) will be compared to the partners of the women who did not.

Data collection:

The source documents will be the medical file and the questionnaires. Clinicians will make the data extraction from the medical files, including the relevant covariables: confounding factors, prognostic factors (e.g., history of depression, anxiolytic treatment before delivery, psychological or psychiatric care before and delivery and after delivery, etc.).

Quality assurance plan:

  • The Investigator undertakes to conduct this study in compliance with Good Clinical Practices and French public health law [Act n°2004-806 dated 9 August 2004 concerning biomedical research, its implementing decree n° 2006-477 dated 26/04/2006, which modifies the portion of the Public Health Code (specifically, Part 1, Book 1, Title II, Section 1) concerning biomedical research, as well as the decrees in force]. The investigator also undertakes to conduct this research in accordance with Declaration of Helsinki of the World Medical Association (Tokyo 2004, as revised).
  • The investigators guarantee the authenticity of the data collected in this study and accept the legal provisions authorizing the study sponsor to set up quality control procedures. During quality control inspections, the following items will be checked:
  • Informed consent.
  • Compliance with the research protocol and the procedures defined there.
  • Assurance of the quality of the data collected in the electronic CRF: accuracy, missing data, consistency of the data with the source documents (such as paper and electronic medical files and questionnaires completed by the midwives).

Reporting for adverse events:

In compliance with decree n° 2006-477 dated 26/04/2006, which modifies the portion of the Public Health Code (specifically, Part 1, Book 1, Title II, Section 1) concerning biomedical research, as well as the decrees in force, any suspected unexpected serious adverse effect will be reported by the Sponsor to the competent, authority at the CPP, as soon as the Sponsor is aware of it and at the latest 7 days after the event.

Sample size assessment:

Psyche 1: For a power of 90%, with a two-sided alpha of 5%, with 2 unexposed subjects for 1 exposed and according to the Australian study by JF Thompson et al. (2011) who found a depression rate of 10% in unexposed and 16% in exposed women at 4 months postpartum, this study requires:

  • 1028 women in the unexposed group, with no hemorrhage
  • and 514 women in exposed group with a hemorrhage

A total of 1542 women must therefore be included.

Statistical analysis plan:

There will be 3 samples for analysis:

  • Respondents to the survey at 2 months
  • Respondents to the survey at 6 months
  • Respondents to the survey at 12 months (not for partners)

The participation and refusal rates will be calculated at each survey point, together with the prevalence of the psychological states studied. Some women will be lost to follow-up at the M6 and M12 surveys. These women will be included in the crude descriptive analyses, and population lost to follow-up will be compared with the study population to look for possible differences in the principal characteristics studied. We plan to perform an interim analysis to assess the need to adjust the study calendar. This interim analysis will be performed after half of the planned subjects have been included.

Statistical techniques:

The statistical methods used for the crude analyses will be a descriptive analysis of the sample with a comparison of the exposed and unexposed groups, where we describe the characteristics of the groups included in the study.

The Chi 2 test (or Fisher's exact test when appropriate) will be used to compare the qualitative variables and Student's t test (or a Mann-Whitney test) for the quantitative variables.

Prevalence rates and their 95% confidence intervals will be calculated for depression at 2 months, 6 months, and 1 year.

A multivariate analysis (logistic regression) will be conducted to take into account confounding factors (smoking, cannabis, etc.) as well as clinically relevant prognostic factors (history of depression, use of anxiolytic or antidepressant agents, etc.) for depression at each survey interval (at 2 months, 6 months, and 1 year). The results will be expressed as adjusted odds ratios (aOR).

At the end of the study, another multivariate analysis (generalized linear mixed model) will be performed to study the trends in the prevalence of depression over the 3 study periods.

Plan for missing data

The missing data will be treated as missing and excluded from the analyses.

Being tested
• The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11., The GAD-7 with a discrimination threshold ≥10., • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46, The IES-R, validated in French, with a discrimination threshold ≥ 30., EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)
Keywords
Postpartum psychological disorders, immediate postpartum hemorrhage.
Medical subject headings
Postpartum Hemorrhage, Depression, Postpartum

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • • The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.Behavioural

    The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.

  • The GAD-7 with a discrimination threshold ≥10.Behavioural

    The GAD-7 with a discrimination threshold ≥10.

  • • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46Behavioural

    Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46

  • The IES-R, validated in French, with a discrimination threshold ≥ 30.Behavioural

    The IES-R, validated in French, with a discrimination threshold ≥ 30.

  • EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)Behavioural

    For the partners

Study groups in NCT03120208
Study groupRoleWhat they receive
women in the nonexposed group without a hemorrhageExperimentalNot described
Receives: Behavioral: • The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.; Behavioral: The GAD-7 with a discrimination threshold ≥10.; Behavioral: • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46; Behavioral: The IES-R, validated in French, with a discrimination threshold ≥ 30.
women in the exposed group with a hemorrhageExperimentalNot described
Receives: Behavioral: • The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.; Behavioral: The GAD-7 with a discrimination threshold ≥10.; Behavioral: • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46; Behavioral: The IES-R, validated in French, with a discrimination threshold ≥ 30.
PartnersExperimentalNot described
Receives: Behavioral: EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. prevalence of depression

    the prevalence of depression, measured by the Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11

    Measured: at 12 months after delivery.

Secondary outcomes (10)
  1. prevalence of depression among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)

    prevalence of depression among women with PPH between 500-1000 mL

    Measured: at 2 months, 6 months, and 12 months after delivery.

  2. The prevalence of depression among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

    The prevalence of depression among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

    Measured: at 2 months, 6 months, and 12 months after delivery

  3. severity of depression among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)

    severity of depression among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)

    Measured: at 2 months, 6 months, and 12 months after delivery

  4. severity of depression among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

    severity of depression among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

    Measured: at 2 months, 6 months, and 12 months after delivery

  5. prevalence of anxiety and post-traumatic stress among women after an immediate PPH

    prevalence of anxiety and post-traumatic stress among women after an immediate PPH

    Measured: at 2 months, 6 months, and 12 months after delivery

  6. prevalence of anxiety and post-traumatic stress among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)

    prevalence of anxiety and post-traumatic stress among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)

    Measured: at 2 months, 6 months, and 12 months after delivery

  7. prevalence of anxiety and post-traumatic stress among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

    prevalence of anxiety and post-traumatic stress among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

    Measured: at 2 months, 6 months, and 12 months after delivery

  8. severity of anxiety and post-traumatic stress among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)

    severity of anxiety and post-traumatic stress among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)

    Measured: at 2 months, 6 months, and 12 months after delivery

  9. severity of anxiety and post-traumatic stress among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

    severity of anxiety and post-traumatic stress among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention

    Measured: at 2 months, 6 months, and 12 months after delivery

  10. prevalence of depression, post-traumatic stress, and anxiety, the experience of delivery, in partners of women with an immediate postpartum hemorrhage (< 24 hours)

    Measured: at 2 months and 6 months after the woman gave birth.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Apr 2017
  2. Study start27 Apr 2017
  3. Primary completion2 Apr 2019
  4. Study completion2 Apr 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,298 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03120208
Sponsor's protocol ID
CHU-314
Other IDs
2016-A00092-49
Acronym
PSYCHE
Status last verified
Aug 2026
First submitted
7 Apr 2017
Last updated
5 Aug 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Pranal M, Legrand A, de Chazeron I, Pr DG, Pr PML, Vendittelli F. Prevalence of maternal psychological disorders after immediate postpartum hemorrhage: a repeated nested cross-sectional survey in a cohort study. BMC Pregnancy Childbirth. 2026 Mar 31;26(1):508. doi: 10.1186/s12884-026-09020-5.

    PubMed 41913127
  • Pranal M, Legrand A, de Chazeron I, Llorca PM, Vendittelli F. Prevalence of maternal psychological disorders after immediate postpartum haemorrhage: a repeated cross-sectional study - the PSYCHE* study protoco. BMJ Open. 2019 Sep 4;9(9):e027390. doi: 10.1136/bmjopen-2018-027390.

    PubMed 31488469

Questions about this trial

What is this clinical trial studying?

A study testing • The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11., The GAD-7 with a discrimination threshold ≥10. and • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46 in people with Postpartum Hemorrhage and Postpartum Women, run by University Hospital, Clermont-Ferrand at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

prevalence of depression (time frame: at 12 months after delivery.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03120208, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in